Intratumoral delivery of liposome-anchored anti-CD137 and IL-2 induces highly potent local and systemic anti-tumor immunity while minimizing toxic inflammatory side effects

brandon kwong,haipeng liu,darrell j irvine

DOI: https://doi.org/10.4049/jimmunol.188.supp.165.6

2012-01-01

Abstract:Immunostimulatory cytokines and antibodies induce potent anti-tumor immune responses in animal models, but also elicit dose-limiting systemic inflammatory toxicity, limiting their effectiveness in the clinic. To address this limitation, we developed a strategy to anchor immunotherapeutics to the surface of lipid nanoparticles (NPs), thus restricting their biodistribution following local injection. We previously demonstrated that NP-coupled anti-CD40 and CpG oligos significantly inhibited growth of s.c. B16F10 tumors, while minimizing systemic exposure to these agents and eliminating the symptoms of inflammatory toxicity associated with soluble agent delivery. Here we have modified this strategy to deliver NP-conjugated anti-CD137 and IL-2. Following local injection into established B16F10 tumors, NP-coupled anti-CD137 + IL-2 therapy enabled complete cure of the primary tumor in nearly 50% of mice and significantly delayed tumor progression in all mice, without systemic inflammatory effects. Importantly, anti-CD137/IL-2-NP therapy also delayed the growth of simultaneous distal untreated tumors, and induced the complete rejection of secondary tumor challenges in 100% of mice. Ongoing experiments are aimed at determining the cellular mechanisms of the combined local and systemic anti-tumor immune response. These results suggest that locally potent immunostimulation can drive systemic anti-tumor immunity without the severe toxicity typically associated with systemic therapy.